JP2022519317A5 - - Google Patents

Info

Publication number
JP2022519317A5
JP2022519317A5 JP2021545964A JP2021545964A JP2022519317A5 JP 2022519317 A5 JP2022519317 A5 JP 2022519317A5 JP 2021545964 A JP2021545964 A JP 2021545964A JP 2021545964 A JP2021545964 A JP 2021545964A JP 2022519317 A5 JP2022519317 A5 JP 2022519317A5
Authority
JP
Japan
Prior art keywords
acid
formula
compound
alcohol
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021545964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519317A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/016876 external-priority patent/WO2020163525A1/en
Publication of JP2022519317A publication Critical patent/JP2022519317A/ja
Publication of JP2022519317A5 publication Critical patent/JP2022519317A5/ja
Priority to JP2024225026A priority Critical patent/JP7781250B2/ja
Pending legal-status Critical Current

Links

JP2021545964A 2019-02-06 2020-02-05 局所ホスホイノシチド3-キナーゼ阻害剤 Pending JP2022519317A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024225026A JP7781250B2 (ja) 2019-02-06 2024-12-20 局所ホスホイノシチド3-キナーゼ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962802093P 2019-02-06 2019-02-06
US62/802,093 2019-02-06
US202062958049P 2020-01-07 2020-01-07
US62/958,049 2020-01-07
PCT/US2020/016876 WO2020163525A1 (en) 2019-02-06 2020-02-05 Topical phosphoinositide 3-kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024225026A Division JP7781250B2 (ja) 2019-02-06 2024-12-20 局所ホスホイノシチド3-キナーゼ阻害剤

Publications (2)

Publication Number Publication Date
JP2022519317A JP2022519317A (ja) 2022-03-22
JP2022519317A5 true JP2022519317A5 (cg-RX-API-DMAC7.html) 2023-02-14

Family

ID=71835949

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021545964A Pending JP2022519317A (ja) 2019-02-06 2020-02-05 局所ホスホイノシチド3-キナーゼ阻害剤
JP2024225026A Active JP7781250B2 (ja) 2019-02-06 2024-12-20 局所ホスホイノシチド3-キナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024225026A Active JP7781250B2 (ja) 2019-02-06 2024-12-20 局所ホスホイノシチド3-キナーゼ阻害剤

Country Status (14)

Country Link
US (2) US11661429B2 (cg-RX-API-DMAC7.html)
EP (1) EP3920911A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022519317A (cg-RX-API-DMAC7.html)
KR (1) KR20210124310A (cg-RX-API-DMAC7.html)
CN (1) CN114072144A (cg-RX-API-DMAC7.html)
AU (1) AU2020219065A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021015353A2 (cg-RX-API-DMAC7.html)
IL (1) IL285020B2 (cg-RX-API-DMAC7.html)
MA (1) MA54907A (cg-RX-API-DMAC7.html)
MX (1) MX2021009142A (cg-RX-API-DMAC7.html)
SA (2) SA521422728B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108274SA (cg-RX-API-DMAC7.html)
TW (1) TWI862548B (cg-RX-API-DMAC7.html)
WO (1) WO2020163525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108274SA (en) 2019-02-06 2021-08-30 Venthera Inc Topical phosphoinositide 3-kinase inhibitors
EP4192431A1 (en) * 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors
EP4401732A4 (en) * 2021-09-15 2025-09-24 Dermbiont Inc COMPOSITIONS AND FORMULATIONS FOR TOPICAL USE OF AN AKT INHIBITOR FOR THE PREVENTION, TREATMENT, AND AMELIORATION OF SKIN DISEASES, CONDITIONS, AND DISORDERS
CN115991716B (zh) * 2021-10-19 2025-10-17 中国药科大学 嘧啶并环类化合物及其衍生物、制备方法、药物组合物和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP3602519B2 (ja) 2002-07-12 2004-12-15 コナミ株式会社 ビデオゲーム装置、画像処理方法及びプログラム
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
WO2007021933A2 (en) 2005-08-12 2007-02-22 The General Hospital Corporation Methods and compositions for use in treating vascular diseases and conditions
US8129371B2 (en) * 2007-10-16 2012-03-06 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
AU2008335156A1 (en) * 2007-12-10 2009-06-18 Metaproteomics, Llc Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith
AU2008363813A1 (en) * 2008-11-07 2010-05-14 Children's Hospital Medical Center Fusogenic properties of saposin C and related proteins and peptides for application to transmembrane drug delivery systems
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
PT2385832E (pt) 2009-01-08 2015-11-02 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
EP2510121A1 (en) 2009-12-11 2012-10-17 Wyeth LLC Phosphatidylinositol-3-kinase pathway biomarkers
CN102268014B (zh) 2010-06-03 2015-06-03 上海艾力斯医药科技有限公司 一类稠合杂芳基衍生物、制备方法及其应用
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
BR112013008615B1 (pt) 2010-10-13 2021-05-11 Medivir Ab composição farmacêutica
CN104010494B (zh) 2011-07-28 2017-07-04 霍夫曼-拉罗奇有限公司 Pik3ca h1047r敲入非人动物乳腺癌模型
US8871781B2 (en) 2011-11-30 2014-10-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject for a lymphatic malformation
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
WO2014046617A1 (en) 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions and methods for treating cancer
EP3294314A4 (en) 2015-05-15 2019-01-16 Memorial Sloan Kettering Cancer Center USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES
JP7051693B2 (ja) 2016-02-19 2022-04-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル PIK3CA関連過成長症候群(PROS CLOVaS症候群)の処置に使用するためのBYL719(アルペリシブ)
EP3251657A1 (en) 2016-05-30 2017-12-06 Sun Pharmaceutical Industries Limited Topical aqueous spray compositions of halobetasol
ES2893527T3 (es) 2016-12-28 2022-02-09 Hisamitsu Pharmaceutical Co Parche
SG11202108274SA (en) 2019-02-06 2021-08-30 Venthera Inc Topical phosphoinositide 3-kinase inhibitors
EP4192431A1 (en) 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors

Similar Documents

Publication Publication Date Title
US11197852B2 (en) Continuous delivery of lenalidomide and other immunomodulatory agents
JP2023002662A5 (cg-RX-API-DMAC7.html)
JP7130818B2 (ja) 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
CN1102850C (zh) 经皮吸收制剂
JP2017214429A5 (cg-RX-API-DMAC7.html)
JP2008543854A5 (cg-RX-API-DMAC7.html)
JP2012521351A5 (cg-RX-API-DMAC7.html)
JP2024544415A5 (cg-RX-API-DMAC7.html)
JP2017513824A5 (cg-RX-API-DMAC7.html)
JPH04504562A (ja) 皮膚疾患及び腫瘍の処理のための製剤
JP2022510587A5 (cg-RX-API-DMAC7.html)
CN1950076A (zh) 含安溴索的局部制剂
JP5593345B2 (ja) イソプロピルウノプロストンの分解抑制方法
RU2014129437A (ru) Офтальмологическая композиция
JP2021525225A5 (cg-RX-API-DMAC7.html)
KR101654028B1 (ko) 피부 도포용 화장료 조성물 및 이의 제조방법
CN1149992C (zh) 活性化合物高度释放的抗真菌凝胶
JP2024525239A5 (cg-RX-API-DMAC7.html)
JP4890856B2 (ja) ジクロフェナク含有貼付剤
JP2018534358A (ja) Vegf阻害剤の局所投与による皮膚障害の処置
JP2024506228A5 (cg-RX-API-DMAC7.html)
JP5816881B2 (ja) 核酸を有効成分とする外用剤組成物
JPH09255578A (ja) 感染性皮膚疾患治療用外用剤
HK40060778A (en) Continuous delivery of lenalidomide and other immunomodulatory agents
RU2005126720A (ru) Спермицидная и/или противогрибковая композиция и способы ее применения